Avonex

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down. ... The appraisal rejected four other interferons - Biogen’s Avonex and long-acting variant Plegridy, Bayer’s Betaferon, and Merck Serono’s Rebif - as well as Teva’s

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

Zinbryta is dosed once a month - less frequently than other MS drugs such as Biogen's own Plegridy and Avonex - and is formulated as a subcutaneous injection that can be administered

Biogen's CEO Scangos to step down

2015, although older injectable MS treatment Avonex (interferon-beta-1a) fell 2% to $606m. ... Long-acting Avonex follow-up Plegridy continued to gain ground - with sales up 65% to $123m - and there were also strong gains for Biogen's haemophilia drugs

Biogen multiple sclerosis drug flunks clinical trial

interferon products Avonex and Plegridy and lower-than-hoped-for volume growth for oral therapy Tecfidera (dimethyl glutamate). .

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Zinbryta (daclizumab) is dosed once a month – in comparison with fortnightly and weekly for Biogen's Plegridy and Avonex, respectively - and is designed to be administered as a subcutaneous injection by ... patients by 45% when compared with Avonex

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]